Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

Ricardo Águas; Adam Mahdi; Rima Shretta; Peter Horby; Martin Landray; Lisa White; the CoMo Consortium

doi:10.1038/s41467-021-21134-2

Nature Communications (Feb 2021)

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

Ricardo Águas,
Adam Mahdi,
Rima Shretta,
Peter Horby,
Martin Landray,
Lisa White,
the CoMo Consortium

Affiliations

Ricardo Águas: Mahidol-Oxford Tropical Medicine Research Unit, Nuffield Department of Medicine, University of Oxford
Adam Mahdi: Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford
Rima Shretta: Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
Peter Horby: Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Martin Landray: Medical Research Council Population Health Research Unit at the University of Oxford, Nuffield Department of Population Health
Lisa White: Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford
the CoMo Consortium

DOI: https://doi.org/10.1038/s41467-021-21134-2
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 8

Abstract

Read online

Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal